Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
RNA Interference01:23

RNA Interference

26.5K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.5K
Gene Therapy00:59

Gene Therapy

25.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>FRMPD4</i>, a causal gene for intellectual disability and epilepsy, is associated with X-linked non-syndromic hearing loss.

medRxiv : the preprint server for health sciences·2026
Same author

From Sound to Stability: Lessons Learned From the CRUSH Study on Hearing Loss Progression and Vestibular Phenotype in Usher Syndrome Type 2A.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2026
Same author

Exploring exon excision as a therapeutic intervention strategy for the future treatment of <i>ADGRV1-</i>associated retinitis pigmentosa.

Molecular therapy. Nucleic acids·2025
Same author

Bi-allelic loss-of-function variants in POC5 cause a syndromic retinal, endocrine, and neuromuscular ciliopathy.

Genetics in medicine : official journal of the American College of Medical Genetics·2025
Same author

Deciphering the largest disease-associated transcript isoforms in the human neural retina with advanced long-read sequencing approaches.

Genome research·2025
Same author

Estimating the Tinnitus Spectrum: A Comparison Between At-Home and Laboratory Measurements.

American journal of audiology·2025

Related Experiment Video

Updated: Sep 21, 2025

Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse
03:52

Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse

Published on: March 2, 2018

10.1K

Altering gene expression using antisense oligonucleotide therapy for hearing loss.

Katelyn N Robillard1, Erik de Vrieze2, Erwin van Wijk2

  • 1Neuroscience Center of Excellence, LSUHSC, New Orleans, LA, USA.

Hearing Research
|June 1, 2022
PubMed
Summary
This summary is machine-generated.

Antisense oligonucleotides (ASOs) offer a promising new treatment for hereditary hearing loss. This review explores preclinical studies on ASO therapies targeting the inner ear for hearing restoration.

Keywords:
Antisense oligonucleotidesDeafnessHearingHearing loss

More Related Videos

Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane
07:32

Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane

Published on: March 16, 2015

16.5K
Canalostomy As a Surgical Approach to Local Drug Delivery into the Inner Ears of Adult and Neonatal Mice
09:34

Canalostomy As a Surgical Approach to Local Drug Delivery into the Inner Ears of Adult and Neonatal Mice

Published on: May 25, 2018

11.0K

Related Experiment Videos

Last Updated: Sep 21, 2025

Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse
03:52

Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse

Published on: March 2, 2018

10.1K
Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane
07:32

Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane

Published on: March 16, 2015

16.5K
Canalostomy As a Surgical Approach to Local Drug Delivery into the Inner Ears of Adult and Neonatal Mice
09:34

Canalostomy As a Surgical Approach to Local Drug Delivery into the Inner Ears of Adult and Neonatal Mice

Published on: May 25, 2018

11.0K

Area of Science:

  • Otolaryngology
  • Genetics
  • Pharmacology

Background:

  • Hearing loss impacts over 430 million globally, affecting development and quality of life.
  • The inner ear is crucial for hearing and balance, serving as a target for therapies.
  • Antisense oligonucleotides (ASOs) are a novel therapeutic approach for genetic disorders.

Purpose of the Study:

  • To review preclinical advancements in antisense oligonucleotide (ASO) therapies for hereditary hearing loss.
  • To focus on ASO mechanisms, preclinical studies, intervention timing, and inner ear delivery.

Main Methods:

  • Review of preclinical research on ASO-based treatments for hearing loss.
  • Analysis of ASO mechanisms of action and gene expression manipulation.
  • Examination of therapeutic intervention timing and inner ear delivery strategies.

Main Results:

  • ASO therapies demonstrate significant promise for treating hereditary hearing loss.
  • Preclinical studies show efficacy in targeting genetic causes of hearing impairment.
  • Optimizing delivery to the inner ear and timing of intervention are key for ASO success.

Conclusions:

  • ASO-based therapies represent a highly promising avenue for addressing hereditary hearing loss.
  • Further research into ASO mechanisms and delivery is crucial for clinical translation.
  • Targeted ASO treatments offer potential for restoring hearing function in affected individuals.